CRMD Earnings Date & History
CorMedix Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:18 PM ET
CorMedix Inc
Pharmaceuticals
- Next earnings date
- Tuesday, November 10, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.09
- Revenue estimate
- $55.0M
CRMD earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $0.24 | $0.29 | +19.4% | $101.9M |
| Thursday, May 14, 2026 | Q1 2026 | $0.37 | $0.49 | +31.7% | $127.4M |
| Thursday, March 5, 2026 | Q4 2025 | $0.83 | $0.16 | -80.8% | $128.6M |
| Wednesday, November 12, 2025 | Q3 2025 | $0.66 | $1.26 | +91.5% | $104.3M |
| Thursday, August 7, 2025 | Q2 2025 | $0.18 | $0.28 | +58.8% | $39.7M |
What the market is watching in CRMD's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next CRMD earnings date?
- CorMedix Inc is scheduled to report on Tuesday, November 10, 2026 (Time TBD). Dates can change until the company confirms them.
- Does CRMD report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for CRMD?
- Consensus EPS for the upcoming quarter is $-0.09, on revenue of $55.0M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
CRMD earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.